Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves

Clinical Epidemiology

Volumn 5, Issue 1, 2013, Pages 205-217

  Chatterjee, Som S ^a   Otto, Michael ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Community associated infection; MRSA; Nosocomial infection; Staphylococcus aureus

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFONICID; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CLINDAMYCIN; DALBAVANCIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; METICILLIN; MINOCYCLINE; ORITAVANCIN; OXACILLIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

AGRICULTURAL WORKER; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; BLOODSTREAM INFECTION; DEBRIDEMENT; DEVICE REMOVAL; EPIDEMIC; HEALTH CARE COST; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROSTHESIS INFECTION; PROSTHETIC VALVE INFECTION; REVIEW; SOFT TISSUE INFECTION; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SURGICAL DRAINAGE; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84879813037     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S37071     Document Type: Review

References (202)

1. Mishra RP, Oviedo-Orta E, Prachi P, Rappuoli R, Bagnoli F. Vaccines and antibiotic resistance. Curr Opin Microbiol. 2012;15:596-602.
2. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629-641.
3. Moellering RC Jr. Past, present, and future of antimicrobial agents. Am J Med. 1995;99:11S-18S.
4. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339: 520-532.
5. Kirby H. Une faute de transcription, d'orthographe, ou d'impression. Science. 1944;100:425-427.
6. Demerec M. Production of Staphylococcus strains resistant to various concentrations of penicillin. Proc Natl Acad Sci U S A. 1945;31:16-24.
7. Murray BE, Moellering RC Jr. Patterns and mechanisms of antibiotic resistance. Med Clin North Am. 1978 62:899-923.
8. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis. 1988;10:677-678.
9. Rountree PM, Freeman BM, Barbour RG. Nasal carriage of Staphylococcus aureus in the general population and its relationship to hospitalization and to penicillin therapy. Med J Aust. 1954;2:457-460.
10. Jevons MP, Parker MT. The evolution of new hospital strains of Staphylococcus aureus. J Clin Pathol. 1964;17:243-250.
11. Jevons MP, Rolinson GN, Knox R. Celbenin-resistant staphylococci. BMJ. 1961;1:124-126.
12. Matsuhashi M, Song MD, Ishino F, et al. Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol. 1986;167: 975-980.
13. Murakami K, Tomasz A. Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus. J Bacteriol. 1989;171:874-879.
14. Ito T, Katayama Y, Hiramatsu K. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315. Antimicrob Agents Chemother. 1999;43: 1449-1458.
15. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2004;39:47-54.
16. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010;375: 1557-1568.
17. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009;119: 2464-2474.
18. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol. 2010;64:143-162.
19. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect. 1993;25:97-108.
20. [No authors listed]. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus -Minnesota and North Dakota, 1997-1999. JAMA. 1999;282:1123-1125.
21. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279:593-598.
22. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003;9:978-984.
23. Otto M. MRSA virulence and spread. Cell Microbiol. 2012;14: 1513-1521.
24. Joshi GS, Spontak JS, Klapper DG, Richardson AR. Arginine catabolic mobile element encoded speG abrogates the unique hypersensitivity of Staphylococcus aureus to exogenous polyamines. Mol Microbiol. 2011;82:9-20.
25. Thurlow LR, Joshi GS, Clark JR, et al. Functional modularity of the arginine catabolic mobile element contributes to the success of USA300 methicillin-resistant Staphylococcus aureus. Cell Host Microbe. 2013;13:100-107.
26. Skov R, Christiansen K, Dancer SJ, et al. Update on the prevention and control of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA). Int J Antimicrob Agents. 2012;39:193-200.
27. Scanvic A, Denic L, Gaillon S, Giry P, Andremont A, Lucet JC. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis. 2001;32:1393-1398.
28. Klevens RM, Morrison MA, Fridkin SK, et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg Infect Dis. 2006;12:1991-1993.
29. Otter JA, French GL. Community-associated meticillin-resistant Staphylococcus aureus: the case for a genotypic definition. J Hosp Infect. 2012;81:143-148.
30. Jimenez JN, Ocampo AM, Vanegas JM, et al. CC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitals. PLoS One. 2012;7:e38576.
31. Tattevin P, Diep BA, Jula M, Perdreau-Remington F. Long-term follow-up of methicillin-resistant Staphylococcus aureus molecular epidemiology after emergence of clone USA300 in San Francisco jail populations. J Clin Microbiol. 2008;46:4056-4057.
32. Tattevin P, Diep BA, Jula M, Perdreau-Remington F. Methicillin-resistant Staphylococcus aureus USA300 clone in long-term care facility. Emerg Infect Dis. 2009;15:953-955.
33. Tenover FC, Tickler IA, Goering RV, Kreiswirth BN, Mediavilla JR, Persing DH. Characterization of nasal and blood culture isolates of methicillin-resistant Staphylococcus aureus from patients in United States Hospitals. Antimicrob Agents Chemother. 2012;56:1324-1330.
34. Abdel-Haq N, Al-Tatari H, Chearskul P, et al. Methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized children: correlation of molecular analysis with clinical presentation and antibiotic susceptibility testing (ABST) results. Eur J Clin Microbiol Infect Dis. 2009;28:547-551.
35. Bradley A. Bovine mastitis: an evolving disease. Vet J. 2002;164: 116-128.
36. Menzies PI, Ramanoon SZ. Mastitis of sheep and goats. Vet Clin North Am Food Anim Pract. 2001;17:333-358, vii.
37. McNamee PT, Smyth JA. Bacterial chondronecrosis with osteomyelitis ('femoral head necrosis') of broiler chickens: a review. Avian Pathol. 2000;29:477-495.
38. Vancraeynest D, Haesebrouck F, Deplano A, et al. International dissemination of a high virulence rabbit Staphylococcus aureus clone. J Vet Med B Infect Dis Vet Public Health. 2006;53:418-422.
39. Cuny C, Friedrich A, Kozytska S, et al. Emergence of methicillin-resistant Staphylococcus aureus (MRSA) in different animal species. Int J Med Microbiol. 2010;300:109-117.
40. Armand-Lefevre L, Ruimy R, Andremont A. Clonal comparison of Staphylococcus aureus isolates from healthy pig farmers, human controls, and pigs. Emerg Infect Dis. 2005;11:711-714.
41. Devriese LA, Van Damme LR, Fameree L. Methicillin (cloxacillin)-resistant Staphylococcus aureus strains isolated from bovine mastitis cases. Zentralbl Veterinarmed B. 1972;19:598-605.
42. Lowder BV, Guinane CM, Ben Zakour NL, et al. Recent human-to-poultry host jump, adaptation, and pandemic spread of Staphylococcus aureus. Proc Natl Acad Sci U S A. 2009;106:19545-19550.
43. Musser JM, Schlievert PM, Chow AW, et al. A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome. Proc Natl Acad Sci U S A. 1990;87:225-229.
44. Devriese LA. A simplified system for biotyping Staphylococcus aureus strains isolated from animal species. J Appl Bacteriol. 1984;56: 215-220.
45. Kloos WE. Natural populations of the genus Staphylococcus. Annu Rev Microbiol. 1980;34:559-592.
46. Fluit AC. Livestock-associated Staphylococcus aureus. Clin Microbiol Infect. 2012;18:735-744.
47. Walther B, Wieler LH, Vincze S, et al. MRSA variant in companion animals. Emerg Infect Dis. 2012;18:2017-2020.
48. Petinaki E, Spiliopoulou I. Methicillin-resistant Staphylococcus aureus among companion and food-chain animals: impact of human contacts. Clin Microbiol Infect. 2012;18:626-634.
49. Morris DO, Lautenbach E, Zaoutis T, Leckerman K, Edelstein PH, Rankin SC. Potential for pet animals to harbour methicillin-resistant Staphylococcus aureus when residing with human MRSA patients. Zoonoses Public Health. 2012;59:286-293.
50. Faires MC, Tater KC, Weese JS. An investigation of methicillin-resistant Staphylococcus aureus colonization in people and pets in the same household with an infected person or infected pet. J Am Vet Med Assoc. 2009;235:540-543.
51. Coughlan K, Olsen KE, Boxrud D, Bender JB. Methicillin-resistant Staphylococcus aureus in resident animals of a long-term care facility. Zoonoses Public Health. 2010;57:220-226.
52. Haenni M, Chatre P, Boisset S, et al. Staphylococcal nasal carriage in calves: multiresistant Staphylococcus sciuri and immune evasion cluster (IEC) genes in methicillin-resistant Staphylococcus aureus ST398. J Antimicrob Chemother. 2011;66:1927-1928.
53. Lin Y, Barker E, Kislow J, et al. Evidence of multiple virulence subtypes in nosocomial and community-associated MRSA genotypes in companion animals from the upper midwestern and northeastern United States. Clin Med Res. 2011;9:7-16.
54. Graham PL 3rd, Lin SX, Larson EL. A US population-based survey of Staphylococcus aureus colonization. Ann Intern Med. 2006;144:318-325.
55. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344:11-16.
56. Schechter-Perkins EM, Mitchell PM, Murray KA, Rubin-Smith JE, Weir S, Gupta K. Prevalence and predictors of nasal and extranasal staphylococcal colonization in patients presenting to the emergency department. Ann Emerg Med. 2011;57:492-499.
57. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis. 2008;197:1226-1234.
58. Tenover FC, McAllister S, Fosheim G, et al. Characterization of Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004. J Clin Microbiol. 2008;46:2837-2841.
59. Creech CB 2nd, Kernodle DS, Alsentzer A, Wilson C, Edwards KM. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J. 2005;24:617-621.
60. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. 1995;31:13-24.
61. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:752-760.
62. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352:468-475.
63. Elie-Turenne MC, Fernandes H, Mediavilla JR, et al. Prevalence and characteristics of Staphylococcus aureus colonization among healthcare professionals in an urban teaching hospital. Infect Control Hosp Epidemiol. 2010;31:574-580.
64. Jarvis WR, Schlosser J, Chinn RY, Tweeten S, Jackson M. National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006. Am J Infect Control. 2007;35:631-637.
65. Fitzgerald JR. Livestock-associated Staphylococcus aureus: origin, evolution and public health threat. Trends Microbiol. 2012;20:192-198.
66. Aiello AE, Lowy FD, Wright LN, Larson EL. Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis. 2006;6:335-341.
67. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148:249-257.
68. Adcock PM, Pastor P, Medley F, Patterson JE, Murphy TV. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis. 1998;178:577-580.
69. Kluytmans JA, Mouton JW, Ijzerman EP, et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis. 1995;171:216-219.
70. Tuazon CU, Perez A, Kishaba T, Sheagren JN. Staphylococcus aureus among insulin-injecting diabetic patients. An increased carrier rate. JAMA. 1975;231:1272.
71. Dinauer MC. Chronic granulomatous disease and other disorders of phagocyte function. Hematology Am Soc Hematol Educ Program. 2005:89-95.
72. Shadyab AH, Crum-Cianflone NF. Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature. HIV Med. 2012;13:319-332.
73. Olsen RJ, Burns KM, Chen L, Kreiswirth BN, Musser JM. Severe necrotizing fasciitis in a human immunodeficiency virus-positive patient caused by methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2008;46:1144-1147.
74. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436-1444.
75. Trilla A, Miro JM. Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. J Chemother. 1995; 7 Suppl 3:37-43.
76. Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop. 2006;26:703-708.
77. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40:100-107.
78. Bassetti M, Trecarichi EM, Mesini A, et al. Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2012;18:862-869.
79. Townell NJ, Munckhof WJ, Nimmo G, et al. Community-associated methicillin-resistant Staphylococcus aureus endocarditis 'down under': case series and literature review. Scand J Infect Dis. 2012;44:536-540.
80. Tattevin P, Schwartz BS, Graber CJ, et al. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2012;55:781-788.
81. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large US database. Crit Care Med. 2006;34:2588-2595.
82. Asai T, Hiki M, Baba K, Usui M, Ishihara K, Tamura Y. Presence of Staphylococcus aureus ST398 and ST9 in swine in Japan. Jpn J Infect Dis. 2012;65:551-552.
83. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006;42:389-391.
84. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13:1840-1846.
85. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001;7:178-182.
86. Gould IM, Reilly J, Bunyan D, Walker A. Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control. Clin Microbiol Infect. 2010;16:1721-1728.
87. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-1771.
88. Hanberger H, Walther S, Leone M, et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents. 2011;38:331-335.
89. Thwaites GE. The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation. PLoS One. 2010;5:e14170.
90. Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31:365-373.
91. Curtis LT. Prevention of hospital-acquired infections: review of non-pharmacological interventions. J Hosp Infect. 2008;69:204-219.
92. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26:166-174.
93. Clancy M, Graepler A, Wilson M, Douglas I, Johnson J, Price CS. Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol. 2006;27:1009-1017.
94. Saavedra-Lozano J, Mejias A, Ahmad N, et al. Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J Pediatr Orthop. 2008;28:569-575.
95. Murillo JL, Cohen M, Kreiswirth B. Results of nasal screening for methicillin-resistant Staphylococcus aureus during a neonatal intensive care unit outbreak. Am J Perinatol. 2010;27:79-81.
96. Mylotte JM, McDermott C. Staphylococcus aureus bacteremia caused by infected intravenous catheters. Am J Infect Control. 1987;15:1-6.
97. Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med. 2006;144:368-370.
98. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-674.
99. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med. 1986;315:91-96.
100. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46 Suppl 5:S368-S377.
101. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol. 2006;44:108-118.
102. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008;49:231-233.
103. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimodt-Møller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med. 2002;162:25-32.
104. Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khati R. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis. 2003;35:782-789.
105. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis. 1998;27:478-486.
106. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285-292.
107. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168:1585-1591.
108. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115:674-680.
109. Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis. 2005;37: 572-578.
110. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis. 2006;38:7-14.
111. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58:273-280.
112. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011;11:208-222.
113. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670-1673.
114. Weigel LM, Clewell DB, Gill SR, et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science. 2003;302:1569-1571.
115. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol. 2008;46:2950-2954.
116. Bae IG, Federspiel JJ, Miro JM, et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis. 2009;200:1355-1366.
117. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2007;30:398-408.
118. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2001;9:486-493.
119. Gould IM. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2011;66 Suppl 4:iv17-iv21.
120. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008;46: 1142-1151.
121. Miller MH, Wexler MA, Steigbigel NH. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob Agents Chemother. 1978;14:336-343.
122. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA. 1995;274:1706-1713.
123. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989;2:1071-1073.
124. Braun L, Craft D, Williams R, Tuamokumo F, Ottolini M. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J. 2005;24:622-626.
125. Ruhe JJ, Menon, A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:3298-3303.
126. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2002;21:530-534.
127. Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents. 2011;37:202-209.
128. Cui L, Isii T, Fukuda M, et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:5222-5233.
129. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:2137-2145.
130. Yang SJ, Kreiswirth BN, Sakoulas G, et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis. 2009;200:1916-1920.
131. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010;50:821-825.
132. Gould IM, David MZ, Esposito S, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012;39:96-104.
133. Mediavilla JR, Chen L, Mathema B, Kreiswirth BN. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA). Curr Opin Microbiol. 2012;15:588-595.
134. Frenay HM, Bunschoten AE, Schouls LM, et al. Molecular typing of methicillin-resistant Staphylococcus aureus on the basis of protein A gene polymorphism. Eur J Clin Microbiol Infect Dis. 1996;15: 60-64.
135. Bannerman TL, Hancock GA, Tenover FC, Miller JM. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol. 1995;33:551-555.
136. Lee SM, Ender M, Adhikari R, et al. Fitness cost of staphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureus by way of continuous culture. Antimicrob Agents Chemother. 2007;51:1497-1499.
137. Collins J, Rudkin J, Recker M, Pozzi C, O'Gara JP, Massey RC. Offsetting virulence and antibiotic resistance costs by MRSA. ISME J. 2010;4:577-584.
138. Deurenberg RH, Stobberingh EE. The molecular evolution of hospital- and community-associated methicillin-resistant Staphylococcus aureus. Curr Mol Med. 2009;9:100-115.
139. Blair JE, Carr M. Distribution of phage groups of Staphylococcus aureus in the years 1927 through 1947. Science. 1960;132:1247-1248.
140. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet. 1978;2:1116-1118.
141. Shands KN, Schmid GP, Dan BB, et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980;303: 1436-1442.
142. Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis. 1981;143: 509-516.
143. Mato R, Campanile F, Stefani S, et al. Clonal types and multidrug resistance patterns of methicillin-resistant Staphylococcus aureus (MRSA) recovered in Italy during the 1990s. Microb Drug Resist. 2004;10:106-113.
144. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A. 2002;99:7687-7692.
145. Coombs GW, Pearson JC, O'Brien FG, Murray RJ, Grubb WB, Christiansen KJ. Methicillin-resistant Staphylococcus aureus clones, Western Australia. Emerg Infect Dis. 2006;12:241-247.
146. Nimmo GR. USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2012;18:725-734.
147. Monecke S, Coombs G, Shore AC, et al. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus. PLoS One. 2011;6:e17936.
148. Uhlemann AC, Dumortier C, Hafer C, et al. Molecular characterization of Staphylococcus aureus from outpatients in the Caribbean reveals the presence of pandemic clones. Eur J Clin Microbiol Infect Dis. 2012;31:505-511.
149. Tavares DA, Sa-Leao R, Miragaia M, de Lencastre H. Large screening of CA-MRSA among Staphylococcus aureus colonizing healthy young children living in two areas (urban and rural) of Portugal. BMC Infect Dis. 2010;10:110.
150. Pan ES, Diep BA, Carleton HA, et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails. Clin Infect Dis. 2003;37:1384-1388.
151. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309-317.
152. Rolo J, Miragaia M, Turlej-Rogacka A, et al. High genetic diversity among community-associated Staphylococcus aureus in Europe: results from a multicenter study. PLoS One. 2012;7:e34768.
153. Reyes J, Rincon S, Diaz L, et al. Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clin Infect Dis. 2009;49:1861-1867.
154. Nichol KA, Adam HJ, Hussain Z, et al. Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69:320-325.
155. Montgomery CP, Boyle-Vavra S, Adem PV, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis. 2008;198:561-570.
156. Li M, Diep BA, Villaruz AE, et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2009;106:5883-5888.
157. Kennedy AD, Otto M, Braughton KR, et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci U S A. 2008;105: 1327-1332.
158. McDougal LK, Fosheim GE, Nicholson A, et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother. 2010;54:3804-3811.
159. Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the midwestern United States. J Clin Microbiol. 2011;49:95-100.
160. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet. 2006;367:731-739.
161. Ito T, Hiramatsu K, Tomasz A, et al. Guidelines for reporting novel mecA gene homologues. Antimicrob Agents Chemother. 2012;56: 4997-4999.
162. Pantosti A. Methicillin-resistant Staphylococcus aureus associated with animals and its relevance to human health. Front Microbiol. 2012;3:127.
163. Garcia-Graells C, Antoine J, Larsen J, Catry B, Skov R, Denis O. Livestock veterinarians at high risk of acquiring methicillin-resistant Staphylococcus aureus ST398. Epidemiol Infect. 2012;140: 383-389.
164. Smith TC, Pearson N. The emergence of Staphylococcus aureus ST398. Vector Borne Zoonotic Dis. 2011;11:327-339.
165. Bhat M, Dumortier C, Taylor BS, et al. Staphylococcus aureus ST398, New York City and Dominican Republic. Emerg Infect Dis. 2009;15: 285-287.
166. van Cleef BA, Monnet DL, Voss A, et al. Livestock-associated methicillin-resistant Staphylococcus aureus in humans, Europe. Emerg Infect Dis. 2011;17:502-505.
167. Meemken D, Blaha T, Tegeler R, et al. Livestock associated methicillin-resistant Staphylococcus aureus (LaMRSA) isolated from lesions of pigs at necropsy in northwest Germany between 2004 and 2007. Zoonoses Public Health. 2010;57:e143-e148.
168. Price LB, Stegger M, Hasman H, et al. Staphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestock. MBio. 2012;3:e305-e311.
169. Mediavilla JR, Chen L, Uhlemann AC, et al. Methicillin-susceptible Staphylococcus aureus ST398, New York and New Jersey, USA. Emerg Infect Dis. 2012;18:700-702.
170. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005;3:948-958.
171. Bartlett AH, Foster TJ, Hayashida A, Park PW. Alpha-toxin facilitates the generation of CXC chemokine gradients and stimulates neutrophil homing in Staphylococcus aureus pneumonia. J Infect Dis. 2008;198:1529-1535.
172. Kobayashi SD, Malachowa N, Whitney AR, et al. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis. 2011;204:937-941.
173. Bubeck Wardenburg J, Bae T, Otto M, DeLeo FR, Schneewind O. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med. 2007;13: 1405-1406.
174. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med. 2008;205:287-294.
175. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis. 2010;202:1050-1058.
176. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med. 2007;13:1510-1514.
177. Periasamy S, Joo HS, Duong AC, et al. How Staphylococcus aureus biofilms develop their characteristic structure. Proc Natl Acad Sci U S A. 2012;109:1281-1286.
178. Surewaard BG, de Haas CJ, Vervoort F, et al. Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis. Cell Microbiol. Epub March 8, 2013.
179. Chatterjee SS, Joo HS, Duong AC, et al. Essential Staphylococcus aureus toxin export system. Nat Med. 2013;19:364-367.
180. Kretschmer D, Gleske AK, Rautenberg M, et al. Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus. Cell Host Microbe. 2010;7:463-473.
181. Yoong P, Torres VJ. The effects of Staphylococcus aureus leukotoxins on the host: cell lysis and beyond. Curr Opin Microbiol. 2013;16:63-69.
182. Malachowa N, DeLeo FR. Mobile genetic elements of Staphylococcus aureus. Cell Mol Life Sci. 2010;67:3057-3071.
183. Loffler B, Hussain M, Grundmeier M, et al. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 2010;6:e1000715.
184. Dumont AL, Nygaard TK, Watkins RL, et al. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol. 2011;79:814-825.
185. Malachowa N, Kobayashi SD, Braughton KR, et al. Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis. 2012;206: 1185-1193.
186. Morinaga N, Kaihou Y, Noda M. Purification, cloning and characterization of variant LukE-LukD with strong leukocidal activity of staphylococcal bi-component leukotoxin family. Microbiol Immunol. 2003;47:81-90.
187. Alonzo F 3rd, Kozhaya L, Rawlings SA, et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature. 2013;493:51-55.
188. Li M, Du X, Villaruz AE, et al. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nat Med. 2012;18: 816-819.
189. DeLeo FR, Kennedy AD, Chen L, et al. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A. 2011;108:18091-18096.
190. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A. 2007;104:9451-9456.
191. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB, Davies JK. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52:3755-3762.
192. Howden BP, McEvoy CR, Allen DL, et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 2011;7:e1002359.
193. Gao W, Chua K, Davies JK, et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog. 2010;6:e1000944.
194. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR. Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. PLoS One. 2011;6:e24301.
195. Uhlemann AC, Kennedy AD, Martens C, Porcella SF, DeLeo FR, Lowy FD. Toward an understanding of the evolution of Staphylococcus aureus strain USA300 during colonization in community households. Genome Biol Evol. 2012;4:1275-1285.
196. Young BC, Golubchik T, Batty EM, et al. Evolutionary dynamics of Staphylococcus aureus during progression from carriage to disease. Proc Natl Acad Sci U S A. 2012;109:4550-4555.
197. Wertheim HF, Vos MC, Boelens HA, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect. 2004;56:321-325.
198. Vos MC, Ott A, Verbrugh HA. Successful search-and-destroy policy for methicillin-resistant Staphylococcus aureus in the Netherlands. J Clin Microbiol. 2005;43:2034; author reply 2034-2035.
199. Graveland H, Wagenaar JA, Heesterbeek H, Mevius D, van Duijkeren E, Heederik D. Methicillin resistant Staphylococcus aureus ST398 in veal calf farming: human MRSA carriage related with animal antimicrobial usage and farm hygiene. PLoS One. 2010;5:e10990.
200. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA. 2010;304:641-648.
201. Johnson AP, Davies J, Guy R, et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother. 2012;67: 802-809.
202. Wyllie DH, Walker AS, Miller R, et al. Decline of meticillin-resistant Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded infection-control intensification. BMJ Open. 2011;1:e000160.